-1.49 %
+6.45 %
+45.86 %
+29.41 %
+12.44 %
-6.38 %
+3.94 %
-56.91 %
-44.59 %
BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.
Read moreMarket cap
653.54M DKK
Turnover
268.87K DKK
Revenue
40.29M
EBIT %
-213.68 %
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 2026-05-22
